Peer-reviewed article
A “Narcotics Contract” for a Patient With Sickle Cell Disease and Chronic Pain
For many physicians, the treatment of chronic pain is one of the most difficult clinical and ethical challenges that they encounter. Patients with chronic pain can be demanding, frustrating, and mystifying. In pediatrics, sickle cell…
For many physicians, the treatment of chronic pain is one of the most difficult clinical and ethical challenges that they encounter. Patients with chronic pain can be demanding, frustrating, and mystifying. In pediatrics, sickle cell disease (SCD) is a common cause of chronic pain. In this issue's “Ethics Rounds,” we present the case of a patient with SCD and ask 2 experts on pain management to discuss the clinical and ethical issues. Carlton Dampier is a professor of pediatrics and assistant dean for clinical research at the Emory University School of Medicine; Carlton Haywood Jr is an assistant professor of medicine and core faculty in bioethics at the Johns Hopkins University.
C.K. is an 18-year-old woman with SCD who has had dozens of hospital admissions and numerous visits to a clinic and the emergency department (ED) for pain crises. Over the previous year she often presented to the ED for treatment of her pain without having first called her hematologists. They have recommended — and stressed — that it would be better to call them first, because they know her and her disease and might be able to manage her pain at home and prevent the need for an ED visit. C.K. has generally listened attentively and promised to call the hematologists before going to the ED, but she then shows up at the ED unannounced.
In the ED, and on the wards when admitted, C.K.'s subjective evaluations of her degree of pain were often at odds with objective parameters such as vital signs and demeanor. Many times she experienced virtually no significant improvement with intravenous ketorolac or hydromorphone dispensed through a patient-controlled analgesia pump. Even an exchange transfusion did not diminish her reported pain despite a postexchange hemoglobin S percentage of zero.
Her doctors recommended psychotherapy. She initially refused …
Address correspondence to John D. Lantos, MD, Children's Mercy Hospital, 2401 Gillham Rd, Kansas City, MO 64108. E-mail: jlantos{at}cmh.edu
Related writing.
Why the Dutch Keep Pediatric Euthanasia Illegal
Pediatric euthanasia in The Netherlands has a unique legal status - it is illegal, openly practiced, and well-regulated. The most surprising part isn't the law that enabled this — it's what happened after.
Associations of Physician Perspectives, Personal Choices, and Counseling for Severe Congenital Heart Defects
OBJECTIVE: To assess whether physicians' perspectives of outcomes or personal choices are associated with prenatal counseling for termination of pregnancy (TOP) or perinatal hospice for severe congenital heart defects (CHDs). METHOD:…
Variation in the extent to which patient information leaflets describe potential benefits and harms of trial interventions: a commentary
Clinical trial participants must understand the possible risks and benefits of trial interventions before providing their informed consent to participate. The aim of this commentary is twofold: to summarize the discrepancies in the extent…
Pediatric Gender Medicine—Reply
Third, emerging evidence suggests that modulating glycosylation pathways could offer a novel therapeutic strategy for asthma management.Xie et al 5 proposed that targeting glycan recognition receptors, such as sialic acid-binding…
About the author
John D. Lantos is a pediatrician and bioethicist writing on AI in medicine, neonatal intensive care, and end-of-life decisions. His essays appear in JAMA, JAMA Pediatrics, the Hastings Center Report, the New England Journal of Medicine, and Aeon. Read more about John.